Investor Updates

Aspen Australia & Emyria enter Registration & Commercialisation Agreement for EMD-RX5
Apr 03, 2023

Aspen Australia & Emyria enter Registration & Commercialisation Agreement for EMD-RX5

Emyria Expands MDMA Analogue Library to Address Mental Health and Neurological Disorders
Mar 19, 2023

Emyria Expands MDMA Analogue Library to Address Mental Health and Neurological Disorders

Emyria partners with PAX Centre for MDMA-assisted therapy
Mar 06, 2023

Emyria partners with PAX Centre for MDMA-assisted therapy

Emyria receives $2m+ R&D tax incentive refund
Jan 12, 2023

Emyria receives $2m+ R&D tax incentive refund

Watch the video – Planet Microcap Showcase Presentation
Dec 14, 2022

Watch the video – Planet Microcap Showcase Presentation

December 7 & 8 Webinars
Dec 06, 2022

December 7 & 8 Webinars

Emyria Company Update – December 2022
Dec 01, 2022

Emyria Company Update – December 2022

Emyria accepted into National Institutes of Health Preclinical Screening Platform for Pain program
Nov 27, 2022

Emyria accepted into National Institutes of Health Preclinical Screening Platform for Pain program

MDMA Webinar recording
Oct 17, 2022

MDMA Webinar recording

MDMA-analogues Webinar – Thursday Oct 13
Oct 10, 2022

MDMA-analogues Webinar – Thursday Oct 13

Have Questions?

If you have any question, please feel free to get in touch with us.

Contact Us

Hit enter to search or ESC to close

Call 08 6559 2800Contact